Study on the Safety and Effectiveness of Different Radiation Doses for High Dose Rate Prostate Brachytherapy

Sponsor: Washington University School of Medicine

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT03424850

Provider View

This clinical trial is exploring the outcomes and side effects of using high dose rate brachytherapy to treat early stage prostate cancer. The study aims to determine the best radiation dose for effective treatment with minimal side effects.

Patient Parameters

Program Overview

The goal of this study is to understand how different doses of high dose rate brachytherapy affect the treatment of early stage prostate cancer. Researchers are looking at both the immediate and long-term side effects to find the most effective and safe dose for patients.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with early stage prostate cancer confirmed by lab tests.
  • Considered low-risk or favorable intermediate-risk based on specific medical criteria.
  • May have started hormone therapy up to 6 months before the brachytherapy and can continue it for 4 to 36 months.
  • Must be at least 18 years old.
  • In good general health with a performance status score of 2 or less, meaning able to carry out all self-care but unable to carry out any work activities.
  • Able to understand and willing to sign a consent form to participate in the study.

Exclusion Criteria

  • Have had previous radiation treatment to the prostate or nearby areas.
  • Have had another type of cancer within the last 5 years, except for certain skin cancers that were treated with surgery.
  • Currently taking part in another clinical trial or using investigational drugs.
  • Have uncontrolled health issues like active infections, severe heart problems, or irregular heartbeats.
  • Unable to have anesthesia for medical procedures.
  • Have had a previous prostate surgery (TURP) that affects the ability to safely perform the brachytherapy.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.